GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xuanzhu Biopharmaceutical Co 2575.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

8.28

-1.08%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Xuanzhu Biopharmaceutical Co

Its shares trade on HKEX under the ticker 2575.HK. It has been listed since 15 October 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥56.1m and a net loss of CN¥266.3m. At that date it held total assets of CN¥1.83bn and shareholders' equity of CN¥1.53bn.

Xuanzhu Biopharmaceutical Co., Ltd. engages in the research and development of chemical and biological drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2025-10-15. The firm is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The firm mainly conducts its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
15 Oct 2025
Employees
197

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Beijing with 197 employees
  • Focuses on R&D, manufacturing, and commercialization of innovative drugs
  • Operates in therapeutic areas including digestion, oncology, and NASH

Weaknesses

  • No specified sector or industry provided
  • IPO scheduled for 2025-10-15, indicating limited market presence
  • Primarily operates in the domestic market with no international expansion mentioned

Opportunities

  • Potential growth in therapeutic areas like oncology and NASH
  • Innovative drug development could attract investment
  • Domestic market focus may benefit from local healthcare trends

Threats

  • IPO date is in the future, creating uncertainty
  • No international market presence increases vulnerability to domestic market fluctuations
  • Lack of sector and industry classification may hinder investor understanding

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.